DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 208624
The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.
Summary for 208624
Tradename: | VIEKIRA XR |
Applicant: | Abbvie Inc |
Ingredient: | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir |
Patents: | 19 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 208624
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624 | NDA | AbbVie Inc. | 0074-0063 | N | 0074-0063-28 |
VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624 | NDA | AbbVie Inc. | 0074-0063 | N | 0074-0063-01 |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 200MG BASE;8.33MG;50MG;33.33MG | ||||
Approval Date: | Jul 22, 2016 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Dec 19, 2019 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ➤ Sign Up | Patent Expiration: | Jul 19, 2019 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ➤ Sign Up | Patent Expiration: | Nov 10, 2020 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription